Serplulimab with chemotherapy and aspirin for untreated small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combination for people with extensive-stage small cell lung cancer that has not been treated before. It adds an immunotherapy drug and aspirin to standard chemotherapy, which may help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have extensive-stage small cell lung cancer that has not been treated with systemic therapy before.
- You have at least one measurable tumor that has not been treated and can be accurately measured on a scan.
- You are in good physical condition (ECOG score 0 or 1).
- You are expected to live at least 3 months.
- You are not currently taking blood thinners other than aspirin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
This trial tests a new combination treatment for extensive-stage small cell lung cancer: intensive chemotherapy plus an immunotherapy drug (adebrelimab), followed by a stem cell transplant using your own cells. The goal is to see if this powerful approach can shrink tumors and help you live longer.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
This trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. It is for those who have not had any previous treatment for their cancer.
This trial tests a new combination of two drugs (YL201 and serplulimab) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the combination helps shrink or control the cancer.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.